These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30582273)

  • 1. The use of biologic agents in the management of uveitis.
    Trivedi A; Katelaris C
    Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Biologic Therapies in Uveitis.
    Schwartzman S; Schwartzman M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):307-16. PubMed ID: 25431348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy for Behçet's uveitis: a systematic review.
    Uke P; Gorodkin R; Beare N
    Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel].
    Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Rev Med Interne; 2018 Sep; 39(9):687-698. PubMed ID: 29610003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting-edge issues in autoimmune uveitis.
    Levy RA; de Andrade FA; Foeldvari I
    Clin Rev Allergy Immunol; 2011 Oct; 41(2):214-23. PubMed ID: 21913066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.
    Pasadhika S; Rosenbaum JT
    Biologics; 2014; 8():67-81. PubMed ID: 24600203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update in treatment of uveitic macular edema.
    Koronis S; Stavrakas P; Balidis M; Kozeis N; Tranos PG
    Drug Des Devel Ther; 2019; 13():667-680. PubMed ID: 30858697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.
    Maleki A; Meese H; Sahawneh H; Foster CS
    Expert Rev Clin Immunol; 2016 Jul; 12(7):775-86. PubMed ID: 26972783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunosuppressive therapy in severe or chronic pediatric uveitis: Review of the literature].
    Stolowy N; Zanin E; Comet A; Jurquet AL; Benso C; Matonti F; Retornaz K; Kaplanski G; Denis D
    J Fr Ophtalmol; 2021 Feb; 44(2):252-258. PubMed ID: 33423814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic agents in experimental autoimmune uveitis.
    Giuliari GP; Sadaka A; Hinkle DM
    Int Ophthalmol; 2014 Feb; 34(1):145-56. PubMed ID: 23494482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of biological treatment for uveitis.
    Gaggiano C; Sota J; Gentileschi S; Caggiano V; Grosso S; Tosi GM; Frediani B; Cantarini L; Fabiani C
    Expert Rev Clin Immunol; 2020 Aug; 16(8):787-811. PubMed ID: 32700605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biological therapy compared to synthetic immunomodulatory drugs or placebo in the treatment of Behçet's disease associated uveitis: a systematic review.
    Urruticoechea-Arana A; Cobo-Ibáñez T; Villaverde-García V; Santos Gómez M; Loza E; Vargas-Osorio K; Fariñas Padrón L; Diaz-Gonzalez F; Calvo-Río V; Blanco R
    Rheumatol Int; 2019 Jan; 39(1):47-58. PubMed ID: 30421105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert opinion on the use of biological therapy in non-infectious uveitis.
    Touhami S; Diwo E; Sève P; Trad S; Bielefeld P; Sène D; Abad S; Brézin A; Quartier P; Koné Paut I; Weber M; Chiquet C; Errera MH; Sellam J; Cacoub P; Kaplanski G; Kodjikian L; Bodaghi B; Saadoun D
    Expert Opin Biol Ther; 2019 May; 19(5):477-490. PubMed ID: 30888881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients.
    Dominguez-Casas LC; Sánchez-Bilbao L; Calvo-Río V; Maíz O; Blanco A; Beltrán E; Martínez-Costa L; Demetrío-Pablo R; Del Buergo MÁ; Rubio-Romero E; Díaz-Valle D; Lopez-Gonzalez R; García-Aparicio ÁM; Mas AJ; Vegas-Revenga N; Castañeda S; Hernández JL; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2020 Aug; 50(4):608-615. PubMed ID: 32497929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.